NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) — Ryah Medtech Inc. (“RYAH” or the “Company”) announced today that it has filed a Medical Device Establishment License application with Health Canada for its commercial grade cannabinoid cartridges. These cartridges are used with RYAH’s ground-breaking dose-measuring medicinal vaporizer for CBD and other cannabinoids or dry herbs.
RYAH is a data aggregation and technology company focused on the global medical cannabis market. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data which is intended to help doctors and patients personalize cannabis to better predict treatment outcomes. With a strong IP portfolio, RYAH is able to gather insightful data on cannabis from seed to consumption.
“This is an exciting milestone in our company’s history,” said Gregory Wagner, President and CEO of RYAH. “The Health Canada initiative will distinguish us from the competitors in the medical cannabis market since there are very few accredited medical vaporizer/cartridge solutions in Canada.”
The RYAH vaporizer is a precision device that is able to capture the amount of vapor a patient inhales. By providing users with unprecedented temperature and dose control, RYAH creates a consistent and reliable vaporizing experience. RYAH uses high-tech disposable medicinal cartridges that have embedded QR codes in order to identify the cartridge’s contents. Coupled with the RYAH application, the RYAH system provides users with the ability to track which cartridges work best for their specific needs and collects data for growers, pharmacies, laboratories and pharma companies. The data is integrated into our big data AI platform, identifying correlations between cannabinoids and medical indications.
“The market is saturated with recreational vaporizer options; however, current products lack the sophistication to create a personalized, accurate dosing and feedback experience,” concluded Mr. Wagner, who reiterated that the state-of-the-art RYAH apparatus comes accompanied with a mobile app that puts the patient or medical practitioner in total control and enables them to collect information to track usage and results.
Several distribution agreements have already been struck with pharma companies in the United States and Canada, and RYAH is targeting entering into similar agreements in Europe and the Asia-Pacific region in due course.